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Platelet-targeted gene therapy with human factor
VIII establishes haemostasis in dogs with
haemophilia A
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It is essential to improve therapies for controlling excessive bleeding in patients with hae-
morrhagic disorders. As activated blood platelets mediate the primary response to vascular
injury, we hypothesize that storage of coagulation Factor VIII within platelets may provide a
locally inducible treatment to maintain haemostasis for haemophilia A. Here we show that
haematopoietic stem cell gene therapy can prevent the occurrence of severe bleeding epi-
sodes in dogs with haemophilia A for at least 2.5 years after transplantation. We employ a
clinically relevant strategy based on a lentiviral vector encoding the ITGA2B gene promoter,
which drives platelet-specific expression of human FVIII permitting storage and release of
FVIII from activated platelets. One animal receives a hybrid molecule of FVIII fused to the von
Willebrand Factor propeptide-D2 domain that traffics FVIII more effectively into a-granules.
The absence of inhibitory antibodies to platelet-derived FVIII indicates that this approach may
have benefit in patients who reject FVIII replacement therapies. Thus, platelet FVIII may
provide effective long-term control of bleeding in patients with haemophilia A.
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T
here are several well characterized inherited genetic defects
that affect various aspects of platelet function and blood
coagulation that usually manifest themselves clinically as a
failure to control bleeding1. Of these, haemophilia A is a
common haemorrhagic disorder (1:10,000 males) linked to
quantitative and/or qualitative defects in the plasma protein
coagulation Factor VIII (FVIII)2,3. A canine model for
haemophilia A exists, which results from a genetic mutation
causing a large inversion of the FVIII gene (that resembles a
molecular genetic defect found in E40% of humans with the
severe haemophilia A)4. Likewise, canine haemophilia A is
essentially identical to the human disease in its clinical
presentation characterized by severe-intermittent episodes of
joint bleeding and haemorrhage. Protein replacement therapy is
the most common treatment of severe bleeding episodes for
haemophilia A but it has been confounded by the formation of
inhibitory antibodies to transfused human FVIII in 30% of
patients5,6. Similarly, 100% of dogs utilized from the Chapel Hill
colony for this study develop inhibitory antibodies after being
transfused with human FVIII (ref. 7), albeit severe bleeding is
successfully treated with canine FVIII supplements. Thus,
canine haemophilia A appears to be an ideal system to
determine whether platelets can be used successfully to deliver
human FVIII to the site of a vascular injury as a feasible
approach to improve haemostasis within a ‘large-animal’ model
of haemophilia A with the ability to form inhibitory antibodies
to human FVIII.
Recent reports indicate that improved therapies are evolving to
control excessive bleeding in patients with severe haemorrhagic
disorders including the use of new therapeutic agents and novel
gene transfer vectors that target production of deficient coagula-
tion proteins within the liver8–11. However, we and others
hypothesized that an autologous transplant of hematopoietic stem
cells transduced with a gene encoding FVIII may be an ideal
approach for correction of haemophilia A within humans12,13. As
activated blood platelets mediate the primary response to vascular
injury by adhering to a wound site and secreting biologically
active proteins14, we hypothesized that synthesis and storage of
FVIII within platelets may be an ideal strategy for providing a
continuous, locally inducible treatment for maintaining
haemostasis for haemophilia A. The use of platelet FVIII to
maintain haemostasis was shown to be a successful approach for
correcting murine haemophilia A15,16, although a suitable
protocol employing platelet FVIII for human gene therapy
remains to be shown as feasible within a large animal model
for haemophilia A. Thus, the current investigation expands
significantly upon platelet gene transfer technology by
demonstrating the development of a clinically relevant strategy
for transferring genes into G-CSF cytokine-mobilized peripheral
blood stem cells (G-PBC) to improve haemostasis for canine
haemophilia A.
To accomplish this goal, a fragment of the integrin aIIb
(ITGA2B) gene promoter known to drive megakaryocyte-specific
gene transcription17 was employed for ectopic expression of
human B-domain-deleted Factor VIII (BDDFVIII) because
megakaryocyte-targeted expression of ITGA2B and integrin b3
(ITGB3) genes was previously shown to be useful for
hematopoietic stem cell gene therapy leading to correction of
platelet function in dogs and mice affected with the inherited
bleeding disorder Glanzmann thrombasthenia (GT)18,19. Second,
herein we show that the VWFSPD2 can help traffic BDDFVIII
efficiently into platelet a-granules (which are secreted from
activated platelets at the vascular injury site). Finally, transient
post-transplant immune suppression is employed in this study to
induce tolerance to platelet BDDFVIII because this approach was
previously shown to be useful in other gene transfer studies7,10,19.
Results
Platelet-targeted lentiviral vector design and strategy. A luci-
ferase reporter assay revealed that fragments of the full-length
human ITGA2B gene promoter permitted comparable platelet-
specific gene transcription (Fig. 1a). Three different ITGA2B
promoter fragments ( 1218,  889 and  673) directed similar
levels of luciferase activity within a pro-megakaryocytic cell line.
In contrast, ITGA2B promoter-driven luciferase activity remained
undetectable in the other blood cell lineages and an epithelial cell
line. Each ITGA2B promoter encodes Ets and GATA factors
permitting a high level of megakaryocyte gene transcription and a
repressor region that inhibits expression within other lineages20.
As a result, two lentiviral gene transfer vectors were tested for
optimal hematopoietic stem cell transduction efficiency and the
ability to improve haemostatic function with platelet-derived
BDDFVIII in haemophilia A dogs to develop a novel strategy that
may prove beneficial for human gene therapy. Two dogs received
an infusion of G-PBC transduced with a lentiviral vector
encoding a fragment beginning at  889 nucleotide of the
human ITGA2B promoter shown to be capable of directing
megakaryocyte-specific transcription of BDDFVIII (Fig. 1b)21.
Although FVIII is absent from platelets under normal conditions,
this approach proved successful for storing viable BDDFVIII in
platelet progeny derived from tissue-cultured human CD34þG-
PBC12 and lentiviral vector-transduced bone marrow
transplanted into haemophilia A mice16. One dog received an
infusion of G-PBC transduced with a novel lentiviral vector
encoding the shortest fragment of the ITGA2B promoter ( 673)
designed to induce megakaryocyte-specific expresson of a hybrid
molecule of BDDFVIII fused to the von Willebrand factor (VWF)
propeptide signal peptide and D2 domain (SPD2) to facilitate
trafficking of BDDFVIII into the a-granule compartment
(Fig. 1c)22,23. VWF is a normal a-granule constituent in human
platelets (albeit absent in canine platelets)24 that serves as a
carrier protein of FVIII in human and canine plasma25.
Strategy for hematopoietic stem cell gene therapy. To design a
clinically relevant protocol, canine hematopoietic stem cells were
mobilized from the bone marrow into the peripheral blood with
canine cytokines (cG-CSF and cSCF) and G-PBC apheresis was
performed without adverse incidents identical to previous studies
using GT dogs19,26. Mononuclear lymphocytes were isolated
with Ficoll-Paque Plus from the apheresis product and then
canine CD34 antigen-positive (CD34þ ) cells were purified by
immunomagnetic selection27. Table 1 summarizes the conditions
for autologous transplant of three haemophilia A dogs transfused
with B3 106 FVIII-transduced CD34þG-PBC per kg of body
weight where each target cell was transduced with B1 104 total
viral particles/CD34þG-PBC without the use of ex vivo or
in vivo selection for transduced cells (columns 4 and 5).
A nonmyeloablative pre-transplant conditioning regimen was
employed to create a niche in the bone marrow for the newly
transplanted cells to engraft (Table 1, column 2). The intensity of
the conditioning regimen is determined by the level at which the
dose becomes toxic to the organs. Earlier studies performed with
normal canine models have demonstrated that stable allogeneic
mixed donor/host hematopoietic chimerism can be safely
established by the administration of a sublethal dose of busulfan
(a drug preferentially toxic to hematopoietic stem cells) for
pre-transplant conditioning. A recent report also demonstrated
successful use of busulfan at 10 mg kg 1 for hematopoietic
stem cell gene transfer to correct canine leukocyte adhesion
deficiency28, followed by transient immunosuppression with
mycophenolate mofetil (MMF) and cyclosporine (CSP) after
major histocompatibility complex identical marrow transplantation29.
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However, this level of pre-transplant conditioning regimen
proved inappropriate for animals with haemophilia A, because
the first dog (F20) transplanted in the current study required daily
supplements with canine (c)FVIII in the form of canine plasma
products and recombinant cFVIII for 3 months after G-PBC
transplant. Epsilon-aminocaproic acid (EACA) was also infused
after G-PBC transplant until human BDDFVIII reached a
significant level in platelets. EACA is an effective synthetic
inhibitor of the plasmin–plasminogen system and controls
subarachnoid haemorrhage, genitourinary bleeding from many
causes and dental surgery in haemophiliacs30. For comparison,
the number of serious bleeding episodes that required treatment
with cFVIII supplement has been recorded 1 year before and 2.5
years after G-PBC transplant for each dog (Table 1, columns 10,
11)31. As a result of the observation of frequent bleeding events
with F20, a milder conditioning regimen consisting of a lower
dose of busulfan was given to the next two transplant recipients
(I42, 5 mg kg 1; M64, 7 mg kg 1). In conclusion, all three
dogs received transient immune suppression10,19,32 and daily
supplements of cFVIII and EACA for 3 months after G-PBC
transplant as a standard transplant regimen until readily
detectable human BDDFVIII levels were observed in platelets
and haemocult tests indicated the absence of GI bleeding10,19,32.
Ultimately, we observed that I42 and M64 did not require further
FVIII supplements as no severe bleeding episodes occurred for 2.5
years after transplant (Table 1, column 11), which will be
discussed in greater detail below.
Biological studies of platelet FVIII. Immuno-confocal micro-
scopy was performed to determine if BDDFVIII was being syn-
thesized and stored in platelets following G-PBC transplant.
Shown in Fig. 2a are images of the results of microscopic analysis
of platelets isolated from one dog (I42) that received an auto-
logous transplant of lentiviral vector-transduced G-PBC, which
represents the outcome of analysis of all three dogs (F20, I42 and
M64). As expected, there was a punctate staining pattern for a
specific marker of platelet a-granules, fibrinogen (Fg) (left panel,
green). Interestingly, human BDDFVIII was also detected in a
punctate pattern within platelets (middle panel, red). Note that
BDDFVIII staining appeared to colocalize frequently with Fg as
evident by the appearance of a yellow staining when the left (Fg)
and middle panel (BDDFVIII) were overlaid, indicating that both
proteins could be stored together within platelet a-granules (right
panel, yellow)12.
Immunoelectron microscopy was performed to determine
whether exogenous BDDFVIII was being transported specifically
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Figure 1 | Platelet-targeted lentiviral vector design. (a) ITGA2B gene promoter fragments direct megakaryocyte-specific expression in luciferase reporter
assay. Human pro-megakaryocytic, lymphocytic, erythrocytic and epithelial cell lines are transfected with a luciferase reporter construct under the control
of one of three fragments of the human ITGA2B gene promoter beginning at either nucleotide  1218(green),  889(yellow) or 673(red) in-frame with
the luciferase gene. A luciferase construct without a gene promoter served as a negative ( )control (peach), whereas a construct with a tissue-
nonspecific gene promoter of the cytomegalovirus (CMV) is a positive (þ )control (blue) arbitrarily assigned a value of 100% luciferase activity. Lysates of
each cell line (x axis) were measured in duplicate on a luminometer to report the percent (%) luciferase activity (y axis) for each construct within each cell
line. Cells were co-transfected with plasmid constructs encoding the marker gene, b-galactosidase, under the under the control of the CMV promoter to
correct for variations in transfection efficiency. Shown is one representative of nine experiments where the error bars represent the s.d. from the mean
value of measurements made in duplicate. (b) 889ITGA2B-BDDFVIII-WPTS lentiviral vector diagram. Shown is the region between the 50-long terminal
repeat (LTR) (left, blue box) and 30-LTR without a U3 enhancer/promoter (right, blue box) to permit the ITGA2B promoter (yellow arrow) to direct
megakaryocyte-specific synthesis of BDDFVIII (grey circle). The 889ITGA2B promoter binds GATA and Ets transcription factors for high-level gene
expression in megakaryocytes and a repressor region inhibits gene expression in other lineages (yellow arrow). The central polypurine tract (cPPT, navy)
and woodchuck hepatitis virus postregulatory element (WPRE, purple diamond) enhance efficiency of transgene expression. (c)  673ITGA2B-VWFSPD2-
BDDFVIII-WPTS lentiviral vector diagram. The backbone of this vector is the same as described in b, except a smaller  673ITGA2B promoter (red arrow)
was fused to DNA encoding the human VWF signal peptide (SP) and D2 domain (peach circle) to traffic BDDFVIII (grey circle) directly to platelet
a–granules.
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ultrathin sections of platelets with a 1Ab to FVIII and a 2Ab
adsorbed on 10-nm gold particles (Fig. 2b). The a-granules
appeared normal in size and shape within platelets of FVIII-
deficient dogs as well as FVIII transplant recipients (blue arrow).
As anticipated, BDDFVIII is absent in platelet a-granules from a
FVIII-deficient negative control (left panel). In contrast,

















































0.8 4.0 106 2.0 108 25.20 1.00 MMF31/
CSP70





1.3 1.25 106 2.0 108 20.00 4.00 MMF45/
CSP91
5.00 0.00 0/2 4.25 2.75
#
M64
7  673 ITGA2B-
VWFSPD2-
BDDFVIII
0.7 4.58 106 2.6 108 22.90 2.00 MMF91/
CSP91
3.00 0.00 0/2 1.25 2.75
CSP, cyclosporine; MMF, mycophenolate mofetil.










































Figure 2 | Synthesis and trafficking of BDDFVIII into canine platelet a-granules. (a) Confocal microscopy showing co-localization of BDDFVIII and Fg
within platelets. Canine CD34þG-PBC were transduced with lentivirions encoding human BDDFVIII followed by transplant haemophilia A dogs. Peripheral
blood platelets were isolated from whole blood, fixed, permeabilized and examined by indirect immunofluorescence analysis for Fg and BDDFVIII
distribution. Shown is a representative image using a  10 eye piece and  100 oil objective and a  2 digital zoom of platelets isolated from one
transplanted animal (I42) from an experiment that was performed seven times on all three dogs and a FVIII-deficient negative control. Fg was visualized
with a 1Ab to this platelet-specific marker for a-granules and a Alexa488-conjugated 2Ab (left, green). BDDFVIII was detected with 1Ab to human
FVIII and an Alexa568-conjugated 2Ab (middle, red). BDDFVIII colocalized with Fg is observed when the two images are merged (right, yellow). The white
scale bar is 5 mm in length. (b) Electron microscopy localized human BDDFVIII directly in a-granules. Shown is a representative image of BDDFVIII
absent from an ultrathin cryosection of a single platelet a-granule (blue arrow) from a FVIII-deficient (negative control, F26) when probed with a 1Ab
(301.3) to human BDDFVIII and a 2Ab-conjugated to 10-nm gold particles. In contrast, BDDFVIII was localized directly within the a-granule (red arrow)
and within intracytoplasmic membrane systems (yellow arrow) in representative images from all three experimental dogs (F20, I42 and M64).
Interestingly, sections from dog (M64) receiving the 673ITGA2B-VWFSPD2-BDDFVIII-transduced G-PBC (VWF-targeting peptide) exhibited a noticably
higher concentration of BDDFVIII within mature platelet a-granules. Each sample was cut on a minimum of three separate occasions with a series of
ultrathin sections subjected to immunogold labelling and analysis of at least 100 a-granules per sample. The white scale bar is 0.2mm in length.
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BDDFVIII was detected within a-granules (red arrows) and
cytoplasm (yellow arrows) of platelets isolated from all three dogs
(F20, I42 and M64). This result is consistent with observations
reported for ectopic expression of BDDFVIII within platelets of
VWF( / ) transgenic mice affected with von Willibrand
disease33. Remarkably,  673ITGA2B-VWFSPD2-BDDFVIII-
transduced platelets from M64 appeared to store the greatest
level of BDDFVIII within the a-granule (right panel). In addition,
BDDFVIII was detected rarely within membrane systems in the
platelet cytoplasm, indicating that the VWFSPD2 indeed had
an increased efficiency to traffic BDDFVIII directly into the
a-granule compartment.
Immunofluorescent flow cytometric analysis of platelets
confirmed that M64 stored the greatest level of FVIII per platelet
because M64 platelets displayed the highest mean fluorescent
intensity for detection of FVIII followed by I42 and F20
compared with FVIII-deficient negative control platelets (Fig. 3).
These results indicate that the VWFSPD2 targeting construct
imparts an advantage for storing BDDFVIII within platelets.
Subsequently, use of the smallest  673ITGA2B gene promoter
allows the lentiviral vector to accommodate the largest
therapeutic insert (in this case, the VWFSPD2–BDDFVIII), and
therefore, may be more useful for gene transfer rather than the
 1218 or  889 ITGA2B promoters.
A Chromogenix Coatest SP4 FVIII assay was performed to
determine whether activated platelets could secrete a biologically
active form of BDDFVIII (FVIII:C) as previously shown for
activated human megakaryocytes in tissue culture12. In Fig. 4,
platelet lysates from a FVIII-deficient dog show that the level of
BDDFVIII:C background activity is virtually unchanged for
untreated (black,  agonist) and activated platelets (white,
þ agonist). In contrast, FVIII:C activity was detected readily in
the lysate of quiescent, untreated platelets from F20, I42 and M64.
Furthermore, BDDFVIII:C levels were decreased in lysates of
platelets stimulated by a mixture of physiological agonists of
platelet activation: ADP, epinephrine and canine PAR1,3,4 in all
three experimental dogs. In summary, dogs that received
BDDFVIII-transduced G-PBC show an appreciable decrease in
FVIII:C activity only after platelet activation, suggesting that
platelets from experimental animals can be induced to secrete
FVIII within the vasculature.
Genomic analysis of the lentiviral vector. The lentiviral vector
WPRE element was detected by PCR of genomic DNA isolated
from leukocytes collected from F20, I42 and M64 for at least 2.5
years after transplant (Fig. 5a). Real time quantitative PCR (RT–
qPCR) analysis of genomic DNA isolated from peripheral blood
leukocytes revealed that the transduction efficiency for each
lentiviral vector was 1% (F20), 4% (I42) and 2% (M64) (Table 1,
column 8). The detection of lentiviral vector by genomic analysis
in the absence of the appearance of insertional oncogenesis is







































Figure 3 | Quantitative analysis of platelet FVIII. Flow cytometric analysis
of platelets. BDDFVIII was absent in platelets (x axis) analysed from a FVIII-
deficient dog used as a negative control for staining with a human BDDFVIII
1Ab and Alexa Fluor 568-conjugated 2Ab (black, unshaded histogram).
In contrast G-PBC from transplanted dogs displayed appreciable levels of
platelet BDDFVIII (shaded histogram:  889ITGA2B-driven FVIII of F20
and I42, yellow;  673ITGA2B-driven FVIII of M64, red). The hierarchy
for the mean fluorescence intensity of FVIII expression reveals that
F20oI42oM64. Shown are the results from one experiment analysis of
50,000 platelets per sample at 2.9 (F20), 1.9 (I42) and 0.9 (M64) years
after infusion of FVIII-transduced G-PBC, which is representative of the


































Figure 4 | Activated platelets induced to secrete FVIII:C. To detect FVIII:
C activity present in lysate of quiescent, untreated platelets (black circle;
( ) agonist) and FVIII:C activity remaining in lysate after secretion of
BDDFVIII from platelets treated with a mixture of physiological agonists of
platelet activation: ADP, epinephrine and canine PAR1,3,4 (white circle: (þ )
agonist). Platelet lysates from a FVIII-deficient negative control dog show
that the level of FVIII:C background activity is virtually unchanged for
untreated and activated platelets. Dogs that received BDDFVIII-transduced
G-PBC show an appreciable decrease in FVIII:C activity only after platelet
activation; thus demonstrating that platelets isolated from experimental
dogs can be induced to secrete FVIII. Each data point represents the mean
value of FVIII:C activity from two independent samples each measured in
duplicate with s.d. represented by black error bars. Shown is the result from
one experiment performed at 2.7 (F20), 1.6 (I42) and 0.6 (M64) years
after infusion of FVIII-transduced G-PBC, which is representative of the
outcome of three separate experiments.
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frequent evaluation of peripheral blood counts and peripheral
blood smears documenting normal morphology and numbers of
circulating hematopoietic cells. Linear amplification-mediated
(LAM)-PCR was also performed to determine the integration
pattern of lentiviral vector within the genome of the experimental
dogs. Figure 5b shows that lentiviral vector was not present
within the genome of a FVIII-deficient control, whereas multiple
bands appear to be present in the genomic DNA of transplanted
dogs (F20, I42 and M64). It is noteworthy that a distinct insertion
site was detected specifically in chromosome 4 for F20 and
chromosome 35 for M64. The results demonstrate that insertion
of the lentiviral vector could be detected within I42 genomic
DNA, although a site of insertion could not be localized to a
precise region of the current canine genome map34. In summary,
the results indicate that insertional mutagenesis had not occurred
when this study was concluded (E2.5 years after transplant).
This is consistent with another report that found lentiviral vectors
usually insert into benign areas of the genome in animals and
humans35. However, oncogenesis as a result of mutagenesis due
to random insertion of the lentiviral vector within the canine
genome remains a potential risk with lentiviral gene transfer.
Efficacy of platelet-targeted gene therapy for haemophilia A.
We observed previously that human hematopoietic cells could
serve as a primary tissue source for the synthesis of a functional
form of human BDDFVIII (FVIII:C) within tissue-cultured
human megakaryocytes12,36, in peripheral blood platelets isolated
from mice xenotransplanted with BDDFVIII-transduced human
G-PBC12, and in a murine model for haemophilia A that received
a transplant of BDDFVIII-transduced bone marrow16. The
current study (Fig. 6) shows that FVIII:C activity (E5–
15 mU ml 1 per 108 platelets) can be detected by chromogenic
analysis for at least 2.5 years after autologous G-PBC transplant
in each dog with the highest levels appearing B1 year after
transplant and typically leveling off to E5–10 mU ml 1 per 108
platelets (F20, I42, M64; blue dashed line). Samples from FVIII-
Deficient dogs served as negative controls for each time point
(black line).
To determine the total level FVIII:C activity present within
each animal at any given time we note that there is E2 108
platelets per ml of blood and there is E92 ml blood per kg in
dogs. Using values recorded in Table 1 for weight and
transduction efficiency and the mean FVIII:C level of each dog
calculated from data points shown in Fig. 6, it is estimated that
there is B0.230U (F20), 1.325U (I42) and 0.676U (M64) FVIII:C
per dog stored within all of the circulating platelets. To put these
values in perspective, the term 1U FVIII:C ml 1 defines 100%
FVIII activity in the reference plasma from a normal (20 kg) dog;
therefore, a normal (20 kg) animal has E800 total units of FVIII
in its plasma volume at any given time.
The results in Fig. 6 show that multiple severe bleeding
episodes occurred in each animal 1 year prior to G-PBC that
required a transfusion with cFVIII supplements (red arrows).
Note, to prevent bleeding due to the gene therapy protocol, each
dog received daily supplements of cFVIII (red bracket) beginning
on day 1 of the G-PBC transplant protocol. EACA (green bracket)
was also administered to the transplanted dogs until blood was
absent from their stool, which remarkably coincided with platelet
FVIII:C levels reaching E5 mU ml 1 per 108 platelets. Interest-
ingly, F20 (top panel) displayed the lowest overall platelet FVIII:
C levels of r5 mU ml 1 per 108 platelets and also experienced
severe intermittent bleeding episodes throughout the experimen-
tal follow-up of 2.5 years after transplant that required
administration of additional supplements in the form of
transfusions of normal canine plasma or cFVIII (red arrows).
This result indicates that 5 mU ml 1 per 108 platelets of FVIII:
C appears to be a threshold level of transgene expression that
must be overcome in canine haemophilia A to achieve adequate
correction of the bleeding phenotype. Transplant dog I42 (middle
panel) maintained the highest steady state of FVIII:C of
B9 mU ml 1 per platelets and did not experience severe
bleeding requiring administration of cFVIII supplements, ulti-
mately demonstrating correction of the haemophilia A phenotype
for at least 2.5 years after transplant. Remarkably, M64 (bottom

































































Figure 5 | PCR analysis for detection and localization of lentiviral vector
within canine genome. (a) Long-term detection of BDDFVIII-lentiviral
vector within leukocyte genomic DNA. Shown is an ethidium bromide-
stained agarose gel of PCR product-derived genomic DNA isolated from
canine peripheral blood leukocytes. Molecular weight markers (Lane 1) are
labelled on the left in base pairs (bp). In Lane 2, p889ITGA2B-BDDFVIII-
WPTS served as a positive control for PCR of a 302 bp region of the
lentiviral WPRE. PCR failed to detect WPRE within leukocyte genomic DNA
from a FVIII-deficient dog serving as a negative control (Lane 3). In
contrast, WPRE was detected in the PCR of all three experimental dogs
(F20, I42, M64; Lanes 4–6) for at least 2.5 years after G-PBC transplant
demonstrating long-term insertion of the lentiviral vector into the canine
genome. All reactions were run in triplicate from at least three separate
samples collected periodically for at least 2.5 years after G-PBC transplant.
(b) Linear amplification-mediated (LAM)-PCR to localize lentiviral vector
within canine genome. Polyacrylamide gel of LAM-PCR products from a
FVIII-deficient negative control and experimental dogs at 2.5 (F20), 1.4
(I42) and 0.5 (M64) years after infusion of FVIII-transduced G-PBC. PCR
was performed on genomic DNA isolated from leukocytes purified with
Ficoll from circulating peripheral blood. Each amplified band represents a
distinct proviral integration. All lanes appear to contain multiple insertions,
indicative of polyclonality. The panel underwent black–white inversion from
the original digital image, and levels were globally adjusted to improve
visibility of all bands. DNA standard markers (Lane 1 and 6) labelled on left
in base pairs.
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the other transplant dogs with the synthesis of a hybrid
SPD2FVIII molecule that obtained a mean FVIII:C activity level
of 8 mU ml 1 per 108 platelets. This result demonstrates that
the use of either the  889ITGA2B gene promoter or the
 673ITGA2B gene promoter coupled with the VWFSPD2
trafficking peptide can be used effectively to target BDDFVIII to
platelets, leading to correction of the canine haemophilia A
phenotype.
The time required for whole blood to clot in a test tube was
measured for each dog using a traditional version of the Lee–
White whole blood clotting time (WBCT) assay37.
Haemostatically normal dogs have a mean WBCT of
10.5 min±s.d. 1.4 min. The baseline WBCT for the FVIII-
deficient dogs was 44.5 (F20), 40.5 (I42) and 460 (M64)
minutes before G-PBC transplant. After G-PBC transplant the
average WBCT decreased to 39.5 (F20, n¼ 5), 38.4 (I42, n¼ 5)
and 41.9 (M64, n¼ 4) minutes. This result shows a very modest
decrease in WBCT, which could be considered well within the
normal variation of WBCT for FVIII-deficient dogs. Interestingly,
this result supports our inability to detect FVIII:C within the
plasma of the experimental dogs (which is an essential
component for success of the WBCT). Thus, this outcome
suggests that measurement of WBCT ex vivo is not a suitable
assay to predict the efficacy for platelet FVIII to improve
haemostasis in vivo because (unlike plasma FVIII) our results
indicate that platelet-derived FVIII must be secreted from
activated platelets following stimulation with physiological
platelet agonists at the site of vascular injury to improve
haemostasis within FVIII-deficient dogs as shown in Figs 4 and 6.
To determine whether the G-PBC transplant recipients
developed a humoral antibody response to the newly expressed
human BDDFVIII, canine blood plasma (from F20, I42 and M64)
was screened for inhibitors with an activated partial thrombo-
plastin time (aPTT) mixing assay that detects inhibitory antibodies
to either coagulation factor VIII or IX. Plasma from haemophilia
A dogs with known Bethesda inhibitor (BIU) titres that crossreact
with and inhibit human FVIII was used as a positive control, and
plasma from dogs without inhibitors was assayed concurrently as
a negative control for comparative analysis. Our results indicate
that F20, I42 and M64 did not develop inhibitors (Table 1: column
12). This result is consistent with our inability to detect the
presence of FVIII:C in the plasma. This outcome is identical with
the failure of haemophilia A mice to develop inhibitory antibodies
to the human platelet BDDFVIII and our the inability to detect
FVIII:C in the plasma following transplant of lentiviral vector-
transduced murine bone marrow16. This further supports our
hypothesis that targeting transgene synthesis of BDDFVIII to
platelets may be a potentially effective treatment for humans with
pre-existing antibodies to FVIII (refs 15,38).
Discussion
Recent reports indicate that haemophilia A may be ameliorated by
targeting expression of human FVIII to the liver by intravenous
infusion of a new generation of adeno-associated viral (AAV)
vectors that appears to show feasibility for restoring haemostasis in
haemophilia A patients32,39. However, AAV clinical trials targeting
liver will likely exclude haemophilia patients with pre-existing liver
damage due to the acquisition of hepatitis or HIV from
contaminated blood products from factor replacement therapy,
or those individuals who have developed inhibitory antibodies to
plasma FVIII or pre-existing immune responses to the AAV
capsid. Thus, an ex vivo approach using the hematopoietic stem
cell as a target for lentiviral gene transfer of FVIII may be an ideal
strategy for B30% of patients with underlying conditions that
exclude them from liver-targeted gene transfer protocols.
Although, it remains to be determined whether a generalized
expression of FVIII within all hematopoietic cell lineages is
sufficient for ecotopic expression of FVIII to correct haemophilia A
in humans40, or if the strategy presented within this report
targeting expression specifically to platelet a-granules has an added
advantage of delivering FVIII directly at the site of the vascular
injury. As the platelet-targeted approach prevents protein
expression within other cell lineages, it may prevent leakage of
FVIII into the blood plasma by cells that do not store FVIII within
granules or expression of FVIII within antigenic cell-types that
could potentially elicit a response from the immune system.
From a quantitative perspective, use of platelet-targeted
synthesis of FVIII results in the production of 0.2-1.3 U FVIII:C
per dog. Although this concentration of FVIII is very modest
compared with the level of FVIII within the plasma of normal
dogs, the data show that our approach is sufficient to provide
20
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Figure 6 | Correction of the canine haemophilia A phenotype with
platelet BDDFVIII. A Coatest SP4 FVIII chromagenic analysis assay was
performed on lysates of 1 108 washed peripheral blood platelets
resuspended in 1 ml of lysis buffer from samples collected periodically for at
least 2.5 years after transplant (x axis). The mean value of FVIII activity
(mU ml per 108 platelets) is represented by the plotting of data points
recorded from two independent samples (each measured in duplicate) with
error bars showing ±s.d. for at least 12 time points (y axis). Analysis of
platelet FVIII:C activity from a FVIII-deficient dog served as a negative
control (black, solid line). Interestingly, the level of FVIII:C activity was
detected above background levels at regular intervals (blue dashed line) for
E2.5 years after transplant of BDDFVIII-transduced G-PBC (F20, top; I42,
middle; M64, bottom panel). Note, each dog was administered daily
injections of FVIII in the form of canine blood transfusions or cFVIII (red
bracket) and EACA (green bracket) for uncontrolled bleeding for a short
time after transplant (until haemocult tests were negative). As anticipated,
each dogs required cFVIII supplements (red arrows) to help resolve severe
bleeding episodes incurred before G-PBC transplant. Remarkably, only F20
(which had the lowest steady state level of FVIII:C activity) required cFVIII
supplements after G-PBC transplant demonstrating platelet FVIII:C activity
reached therapeutic levels in I42 and M64.
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therapeutic benefit for I42 and M64 for at least 2.5 years after
G-PBC transplant (please see records of post-transplant bleeding
events depicted in Table 1 (column 11) and Fig. 6). This is
consistent with the observation that from a cofactor perspective,
in the presence of calcium and phospholipids even trace amounts
of FVIII can increase the conversion of FX to FXa by FIXa to
levels with therapeutic effects. Thus the outcome of this study
indicates that secretion of FVIII by platelets precisely at the site of
the vascular injury is likely be a feasible and clinically relevant
strategy for establishing haemostasis in patients affected with
haemophilia A.
It is important to note that the lack of spontaneous formation
of antibodies to human FVIII is not necessarily evidence of
immune tolerance induction. The absence of inhibitory anti-
bodies may be the direct consequence of ‘sequestering’ the FVIII
(which is normally a plasma protein) within platelet a-granules.
Furthermore, the sub-myeloablative condition regimen utilized to
create a niche in the bone marrow for the engraftment of the
lentiviral vector-transduced G-PBC may have played a role
towards our inability to detect inhibitory Ab to human
BDDFVIII. This is supported by our previous report that
transient immune suppression with intravenous immunoglobu-
lin, cyclosporine and prednisone were used to successfully
diminish an immune response that developed in a GT dog
transplanted with G-PBC transduced with a lentiviral vector
expressing ITGA2B on platelets19. This is consistent with another
report where immune suppression helped diminish an immune
response in non-human primates that developed inhibitory
antibodies to human FVIII (ref. 39). Clearly, the strategy for
platelet FVIII gene transfer does not appear to elicit the formation
of inhibitory antibodies, although this topic requires further study.
Interestingly, (following G-PBC pre-transplant and condition-
ing) F20 successfully fathered a litter of pups affected with
haemophilia A with no other detectible abnormalities. As use of
chemotherapeutic agents for pre-transplant condition and
transient immune suppression carries the risk of side-effects
and sterility, data from this study suggest that the particular pre-
transplant conditioning regimen with busulfan followed by a
short course of immune suppression with MMF and CSP used in
this study does not appear to affect the ability of the dog to
produce viable offspring. Note, I42 and M64 received a lower
dose of busulfan preconditioning than F20 (Table 1, column 2),
yet it remains to be determined whether these dogs have also
remained fertile because they were not used to father litters after
gene transfer. Although, the likelihood that the single dose pre-
transplant conditioning regimen did not affect fertility is
consistent with well-established clinical information from
patients that received a single dose of conditioning with
busulfan41,42.
Collectively, our results demonstrate that hematopoietic
G-PBC gene transfer provides long-term correction of the
haemophilia A bleeding phenotype in dogs. This outcome is
consistent with our previous studies showing successful expres-
sion of FVIII within a human transformed megakaryocyte cell
line, and the feasibility of platelet factor VIII to restore
haemostasis in the murine haemophilia A15,16. The current
work demonstrates feasibility of targeting BDDFVIII specifically
in platelets to improve haemostasis within a canine ‘large-animal’
model of haemophilia A. This work indicates precedence for
proposing trials to determine whether this clinically relevant
strategy demonstrated herein for targeting BDDFVIII into
platelets has the ability to provide therapeutic benefit for
human haemophilia A patients. This study also paves the way
for better management of patients with other inherited platelet
bleeding diseases and potentially a wide spectrum of disorders
because platelets have a role in many cellular processes1.
Methods
Human transformed cell lines. Pro-megakaryocytic (HEL)43,44, T-cell lymphoma
(KT1)45, B-cell lymphoma (Raji)46, erythroleukemia (K562)47, and epithelial
(HeLa)48 cells were obtained from American Type Culture Collection (Rockville,
MD, USA).
Luciferase reporter gene promoter vectors.. ITGA2B Gene Promoter Con-
structs: Genomic DNA was isolated from the human pro-megakaryocyte cell line,
Dami49, and human ITGA2B gene promoter fragments were amplified by PCR
using either sense primer ‘ 1218’(50-TTACGCGTCGACAGATCTAAATGTGG
CTGGTTACCCC-30)‘ 1198’ (bold) of ITGA2B or ‘-889’(50-TTACGCGTCG
ACAGATCTGTGCTCAATGCTGTGCC-30)‘-872’ (bold) of ITGA2B or
‘ 673’(50-TTACGCGTCGACAGATCTCCTTGCCACCTAGACC-30)‘ 654’
(bold) of ITGA2B and anti-sense primer (50-GGCGTCTTCCATGGTCCTTCTT
CCACAACC-30) encoding nucleotides þ 99 to þ 86 of luciferase pGL3-BASIC
and nucleotides þ 30 to þ 15 (bold) of ITGA2B gene promoter. Correct identity of
constructs was confirmed by nucleotide sequence analysis.
pCMVLuc: A BglII and HindIII restriction digest of cytomegalovirus tissue
nonspecific gene promoter (878 bp) from pRc/CMV (Invitrogen) is ligated into the
pGL3-Basic Luciferase vector (Promega, Madison, WI). This construct served as
the positive control for high level gene expression within all cell types, thus,
assigned an arbitrary level of 100% luciferase activity for each cell line (Fig. 1).
pGL3-BasicLuc: negative control construct for 0% luciferase activity (Fig. 1)
because lacks a gene promoter to drive luciferase gene transcription (Promega).
pCMVnlac: Cell lines were co-transfected with one of the pITGA2BLucþ
constructs and pCMVnlac encoding the b-galactosidase marker gene to normalize
transgene expression49.
Luciferase gene promoter reporter assay. Cell lines (2 107) were co-trans-
fected with either (20 mg) of the ITGA2B gene promoter construct ( 1218,  889,
 673) (Fig. 1a) or the positive (CMV) or negative (Basic) controls encoding firefly
luciferase and pCMVnlac (20 mg) encoding b-galactosidase49. Briefly, 48 hours after
co-transfection cells were washed, harvested and lysates were prepared and frozen
to  80 C using the luciferase assay system (Promega). Luciferase activity was
measured with a Turner Designs Model 20 Luminometer. Detection of b-
galactosidase activity was performed to normalize transient transgene expression
for each cell line with a sensitive ELISA enzymatic assay that measured colormetric
change with the substrate for b-galactosidase, chlorophenol red b-D-
galactopyranoside (CPRG)50. The percent of luciferase activity was determined by
comparing the mean value of the relative light units (RLU) of luciferase/CPRG
Vmax value for each construct to reveal the transfection efficiency for each cell line.
The RLU for pCMVLuc was assigned arbitrarily a value of 100% and all other
results were calculated for each vector based upon that value as shown in Fig. 1a.
ITGA2B promoter-driven lentiviral vector for human BDDFVIII. ITGA2B-
WPTS genetic transfer vectors are derived from a HIV type-1 lentiviral vector
(D.Trono, University of Geneva, Switzerland)51. p 889ITGA2B-BDDFVIII-
WPTS lentiviral vector (Fig. 1b) encodes a  889 to þ 30 nucleotide fragment of
the human ITGA2B promoter and human BDDFVIII molecule16.
p 673ITGA2BVWFSPD2-BDDFVIII-WPTS lentiviral vector (Fig. 1c) encodes
a fragment of the human ITGA2B gene promoter from nucleotide  673 to þ 30
followed by a fragment of the human Von Willebrand Factor propeptide (VWFpp)
encoding the VWF signal peptide (SP;66 bp) linked to the D2 domain(1,199 bp)
and cDNA encoding human BDDFVIII to allow megakaryocyte-specific
transcription of a hybrid molecule that uses the SPD2 peptide to traffic human
BDDFVIII to platelet a-granules22. cDNA encoding SP was amplified by PCR with
forward primer (P)1 (50-GTTAATCGATATCTCCTTGCCACCTAGA-30) and
reverse P2 (50-AATCTGGCAGGAATCATGGTCCTTCTTCCACAACCT-30) and
ligated to D2 amplified by PCR using forward P3 (50-AGGTTGTGGAAGAAGGA
CCATGATTCCTGCCAGATTTGC-30) and reverse P4 (50-CGTCTCGGCCCTTT
TGCTGCCATGAGACAG-30). A nested PCR-linked ITGA2B promoter and
VWFSPD2 with P5 (50-ATCGATATCTCCTTGCCACCT A-30) and P4.
p 889ITGA2-BDDFVIII-WPTS served as a template for PCR of cDNA encoding
a fragment of BDDFVIII using forward P7 (50-CGTCTCAGGGCCACCAGAAG
ATACTACCT-30) and reverse P8 (50-ACGCGTCTTCTCTACATACTAGTA-30)
to synthesize cDNA that ligated directly to VWFD2. All PCR products were cloned
into pCR-Blunt II-TOPO (Life Technologies, Grand Island, NY) using unique
restriction sites  673ITGA2B-SPD2(ClaI and BsmBI) ligated to 50hBDDFVIII
(BsmB1 and MluI) with 30BDDFVIII (MluI and Spel). All fragments were cloned
into pWPTS lentiviral vector and the correct identity confirmed by nucleotide
sequence analysis. Recombinant virions were generated from three-plasmid
transient co-transfection followed by supernatant collection, 500-fold
concentration by centrifugation and storage at  80 C until utilized19. Virion titre
was determined by RT–PCR52. Replication-competent virions were confirmed
absent from stocks with marker rescue assays26.
Dogs. Cytokine mobilized CD34þG-PBC gene transfer and autologous transplant
studies using FVIII-deficient dogs affected with haemophilia A (University of
North Carolina, Chapel Hill, NC)4 were conducted and approved by Institutional
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Animal Care and Use Committees of the University of North Carolina and The
Medical College of Wisconsin, which are both accredited facilities of the American
Association for Accreditation of Laboratory Animal Care.
CD34þ G-PBC isolation and transplantation of transduced cells. Adult (1.25,
4.25 and 6.5-year-old) FVIII-deficient male dogs were injected daily with canine
recombinant granulocyte colony stimulating factor (crG-CSF; 10 mg kg 1 d 1)
and stem cell factor (crSCF; 5 mg kg 1 d 1) (Amgen, Thousand Oaks, CA, USA).
G-PBC collection was performed on the third day using a COBE Spectra Blood Cell
Separator. Mononuclear G-PBC were isolated with Fico-Paque Plus (GE Health-
care, Uppsala, Sweden). CD34þ G-PBC were selected with a biotin-conjugated-
1H6 Ab (1 mg ml 1) (Richard Nash, Fred Hutchinson Research Institute, Seattle,
WA, USA) and anti-biotin immuno-magnetic beads (1:5 dilution) on an Automacs
magnetic cell separator (Miltenyi Biotec Inc., Auburn, CA, USA).
CD34þG-PBC were transduced with  889ITGA2B-BDDFVIII-WPTS or
 673ITGA2B-VWFSPD2-BDDFVIII-WPTS lentiviral vector. Briefly, 4 106 cells
per well were seeded in a six-well plate (Falcon-Becton Dickinson, Franklin Lakes,
NJ, USA) coated with 20 mg cm 2 RetroNectin (Takara Shuzo, Otsu, Shiga, Japan)
and incubated with 1.0 104 ITGA2B–FVIII lentivirions per cell in X-Vivo 10
containing 10% FCS, rhIL-3, rcaIL-6, rcaSCF, rhTPO and rhflk2/flt3 ligand.
Approximately 3 106 FVIII-transduced CD34þG-PBC per kg and 2 108
CD34( ) G-PBC were infused into the cephalic vein of each autologous transplant
recipient pre-conditioned with a nonmyeloablative dose of 5-10 mg per kg
Busulfex. Transient immune suppression administered for E90 days after
transplant with 10 mg kg 1 per day cyclosporine (Gengraf, Abbott Laboratories,
North Chicago, IL, USA) and 8 mg kg 1 per day MMF (Table 1)19.
Blood collection. Blood was collected at preselected times into a vacutube con-
taining 7.5% EDTA anticoagulant19. Blood cells were counted on a Vet ABC
haematology analyser (scil animal care company, Gurnee, IL, USA). Platelets were
isolated with Fico/Lite (Atlanta Biologicals, Norcross, GA, USA), washed with PBS
and used directly for immunofluorescent flow cytometry or FVIII:C activity
analysis. Leukocytes were isolated with Ficoll-Paque Plus (GE Healthcare)
according to the manufacturer’s specifications.
Antibodies. A murine monoclonal 1Ab to canine CD34 ‘1H6’ (1 mg ml 1) was
from the Fred Hutchinson Cancer Research Center (Seattle, WA, USA)27. A sheep
anti-rabbit fibrinogen polyclonal 1Ab (5mg ml 1) that recognizes canine
fibrinogen was purchased from Enzyme Research. Monoclonal 1Abs (5–
10mg ml 1), MBC 103.3 and 301.3 (R.R. Montgomery, BloodCenter of WI,
Milwaukee, WI, USA) recognize epitopes on human BDDFVIII (ref. 53). 2Abs
used were Alexa Fluor 488 F(ab0)2 conjugated to a fragment of donkey anti-sheep
IgG (Hþ L) (1:1,000 dilution) and Alexa Fluor 568 F(ab0)2 fragment of goat anti-
mouse IgG (Hþ L) (1:500 dilution) were from Life Technologies (Grand Island,
NY, USA).
Immunofluorescent confocal microscopy. Canine platelets were fixed with 3.7%
(vol/vol) buffered formalin, permeabilized in 0.5% Triton X-100 (in 20 mmol l 1
Hepes, 300 mmol l 1 sucrose, 50 mmol l 1 NaCl and 3 mmol l 1 MgCl2, pH 7.0)
and blocked with 2.5% normal goat serum in HBSS. Platelets were incubated with a
sheep polyclonal 1Ab to canine fibrinogen and monoclonal 1Ab (MBC 103.3 and
301.3) to human FVIII (5mg ml 1) overnight at 4 C53. The Alexa Fluor 488-
conjugated F(ab0)2 fragment of donkey anti-sheep IgG (Hþ L) was used as a 2Ab
(1:1,000 dilution) to detect fibrinogen and Alexa Fluor 568-conjugated F(ab0)2
fragment of goat anti-mouse IgG (Hþ L)-conjugated 2Ab (1:500 dilution) was used
to detect the presence of FVIII for 30 min at 25 C. Platelets were mounted with
Vectashield (Vector Labs, Burlingame, CA, USA). Immunofluorescence was detected
with a Zeiss LSM 510 Multiphoton Confocal Microscope (Carl Zeiss, Inc.
Oberkochen, Germany)54. Platelets isolated from FVIII-deficient dogs were used as
negative controls. Nonspecific isotype control Ab served as negative controls.
Platelets were imaged by Z sections taken for each field and the entire Z series (12-25
images) combined into a stacked projection. The projections were merged using the
Confocal Assistant software programme (Bio-Rad). Computer-assigned colours were
based on the intensities of bitmap overlaps, with Alexa488-fluorochrome represented
by green pixels, Alexa568-fluorochrome represented by red pixels and colocalization
of the two fluorochrome-conjugated antibodies represented by yellow pixels.
Immunofluorescent flow cytometry. Canine platelets were isolated from blood
and treated with Cytofix and PERM/WASH reagents (BD Biosciences) for intra-
cellular detection of BDDFVIII. Platelets were incubated with a monoclonal 1Ab
(MBC 103.3 and 301.3) to human FVIII (5 mg ml 1) 30 min at 4 C and then
incubated with Alexa Fluor 568-conjugated F(ab0)2 fragment of goat anti-mouse
IgG (Hþ L) conjugated 2Ab (1:500 dilution) for 30 min at 4 C. Platelets isolated
from FVIII-deficient dogs were used as negative controls. Nonspecific isotype
control Ab served as negative controls. Cells were collected and analysed on an
Accuri C6 Flow Cytometer (Accuri Cytometers, Inc., Ann Arbor, MI, USA) using
the Accuri analysis software.
Immunogold labelling. Platelets were fixed in 1.25% glutaraldehyde (Fluka AG,
Buchs, Switzerland), infused with 2.3 M sucrose (Fluka) and frozen with a Reichert
KF 80 freezing system (Leica, Vienna, Austria). Sections of E80 nm were prepared
with the Ultracut E ultramicrotome equipped with a FC 4E cryokit attachment and
placed on collodion-coated nickel grids. Grids were incubated for 10 min on PBS
with 1% BSA and then placed on (10 mg ml 1) drops of the 1Ab to FVIII (301.3)
for 1 h at 25 C. Sections were incubated for 1 h with a goat anti-mouse 2Ab
adsorbed onto 10-nm gold particles (1/100 dilution of AuroProbe EM G10).
Controls included the use of an irrelevant IgG of the same species and at the same
concentration.
Electron microscopy. Grids were stained by uranyl acetate and osmium and then
embedded in methylcellulose prior to observation with a Jeol JEM-1010 trans-
mission electron microscope (Jeol, Croissy-sur-seine, France) at 80 KV.
Agonist-induced activation of platelets. Platelets were isolated from circulating
peripheral blood, washed and activated with physiological agonists of platelet acti-
vation. To induce activation, platelets were resuspended in Tyrode’s buffer (2.5 106
per ml) containing 1 mM CaCl2, 1 mM MgCl2, 25mM each of adenosine diphosphate
(ADP) (Sigma), epinephrine (Bio/Data Corporation, Horsham, PA, USA) and
canine thrombin receptor activating peptides (synthesized in our core laboratory):
PAR1 (SFFLKN-NH2), PAR3 (TRFGAP-NH2) and PAR4 (SFPGQP-NH2) for
30 min at 37 C as previously described19,31. Separate aliquots were incubated in
Tyrode’s buffer without agonist as a negative control. The platelets were pelleted by
centrifugation and supernatant was aspirated and discarded from agonist-treated
and negative control samples. The platelet pellet was frozen immediately to  80 C
until being tested for FVIII:C activity using the coatest assay.
PCR detection of lentiviral vector in blood genomic DNA. DNA was isolated
with a QIAamp DNA Blood Mini Kit (Qiagen, MD, USA) from canine leukocytes
purified with Ficoll-Paque Plus (Amersham Pharmacia Biotech AB, Uppsala,
Sweden). p 889ITGA2-BDDFVIII-WPTS served as a positive control. PCR
analysis was performed with Taq polymerase (Invitrogen, Carlsbad, CA, USA) on a
PTC200 instrument (MJ Research, Watertown, MA) with forward primer P1 (50-
ACGCTATGTGGATACGCTG-30) and reverse primer P2 (50-AACACCACG-
GAATTGTCAG-30) to synthesize a 318 nucleotide primary product encoding the
WPRE (Fig. 1b,c). A secondary PCR reaction was performed with nested forward
primer P3 (50-TGGATACGCTGCTTTAATGC-30) and reverse primer P4 (50-
AATTGTCAGTGCCCAACAG-30) encoding a 302 bp product of WPRE (Fig. 5a).
RT–qPCR to detect lentiviral transduction efficiency. Percent lentiviral gene
marking was measured by RT–qPCR using Bio-Rad CFX96 Real-Time System52.
Briefly, 12.5 ml of TaqMan Universal PCR Master Mix (Life technologies), a 900 nM
concentration of each primer and 200 nM probe were combined in 20 ml of water.
Then, 5 ml of canine genomic DNA was added and PCR was performed as follows:
2 min at 50 C, 10 min at 95 C, and then 40 cycles of 15 s at 95 C and 1 min at
60 C. For each RT–qPCR, a no-template control was included as negative control.
Each sample was analysed in triplicate for gene copy number using Primer Express
software (version 1.0; Applied Biosystems) and the mean value for transgene copy
number/genome was converted to percent peripheral blood cells positive for
lentiviral vector (also known as transduction efficiency) and reported in Table 1
(column 8). The lentiviral LTR primers and probe used were: forward: 50-AGCT
TGCCTTGAGTGCTTCA-30 ; reverse: 50-TGACTAAAAGGGTCTGAGGGA-30 ;
probe: 6FAM 50-TGCCCGTCTGTTGTGTGACTCTG-30 MGBNFQ. The canine
ITGB3 gene was used as an endogenous control for gene copy number with
forward :50-ATGCATCCCACTTGCTGGTAT-30 ; reverse: 50-TGCCCATCGTTA
GGTTGG-30 ; probe: 6FAM50-TGCCTGCCAGCCTTCCATCCAG-30 MGBNFG.
Copy number was based on TaqMan principle. Ten-fold serial dilution of the
plasmid constructs of known concentration containing relevant sequences
(lentiviral vector LTR and canine ITGB3) were used to create standard curves for
quantification of samples.
Linear amplification-mediated PCR. LAM–PCR was performed to localize the
lentiviral vector insertion sites within genomic DNA isolated from peripheral blood
leukocytes. Briefly, the junction between integrated proviral LTR and the host
genome was selected by two rounds of linear PCR (95 C for 5 min (95 C for
1 min, 60 C for 45 s, 72 C for 90 s)  50; 72 C for 10 min) with a vector-specific
50-biotinylated primer (50-/biotin/-GAACCCACTGCTTAAGCCTCA-30) and
purified using streptavidin-coated magnetic beads (Dynal M-280). Products were
double-stranded using Klenow polymerase and random hexanucleotide primers
and digested with Tsp509I at 65 C for 2 h. Directional double-stranded linker
oligos were ligated onto the non-LTR end and the resulting products were
amplified by nested PCR (95 C for 5 min (95 C for 1 min, 60 C for 45 s, 72 C for
90 s)  35; 72 C for 10 min) using LTR-specific forward primers (F1: 50-/biotin/-
AGCTTGCCTTGAGTGCTTCA-30 ; F2: 50-AGTAGTGTGTGCCCGTCTGT-30)
and linker cassette specific reverse primers (R1: 50-GACCCGGGAGATCT
GAATTC-30 ; R2: 50-AGTGGCACAGCAGTTAGG-30). Between rounds of nested
PCR, products were purified using streptavidin-coated magnetic beads. Products
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were visualized on 2% TAE agarose gels. For sequencing, products were gel-pur-
ified and cloned into pCR2.1-TOPO, transformed into E. coli Top10, selected on
LB-Amp-Xgal plates and amplified by colony PCR using M13F/R.
Functional assessment of integration sites. Sequence products from LAM–PCR
that were verified to contain proviral LTR sequence were masked for known
genomic repeats and proviral features. The resulting sequence was aligned to the
dog genome (CanFam 2.0, May 2005 assembly) using the Blat (BLAST-like align-
ment tool) server at UCSC. Sequences mapping to a unique location in the genome
at 95% similarity were selected and integration sites were determined as the base in
the genomic alignment flanking the proviral LTR sequence. For each site, the closest
RefSeq gene was determined and compared with a list of human cancer orthologs.
Detection of biologically active human FVIII (FVIII:C). Lysates of 1 108 pla-
telets per ml were tested for FVIII:C using a Chromogenix Coatest SP4 FVIII kit
(DiaPharma, Franklin, OH, USA)12. Duplicate samples of supernatant were placed
in uncoated wells of a 96-well microtiter plate (25 ml per well) and assay
components (phospholipid, Factor IXa, Factor X and calcium chloride) were added
and incubated for 10 min at 37 C. The chromogenic Factor Xa substrate S-675 was
added and the plate was transferred to a Wallac Victor2 microplate reader preset at
37 C. The Factor Xa-dependent conversion of S-2675 is directly related of the
amount of FVIII:C in each well. A standard curve was constructed by plotting
known amounts of recombinant human FVIII (Kogenate; Bayer Healthcare
Pharmaceuticals, Berkeley, CA, USA) diluted in platelet lysate buffer using Vmax at
405 nm. The Vmax of each reaction was converted to units of FVIII:C activity using
the kinetic software programme, SOFTmax, v.2.34 (Molecular Devices). The FVIII
activity was measured by an endpoint reading at 405 nm, a background reading at
490 nm was subtracted from 405 nm. The total maximum FVIII:C per dog was
calculated by multiplying the mean FVIII:C U ml per 1 108 platelets 92 ml
blood/kg dog weight (kg) 2 108 platelets per ml of blood using measured
values recorded in Table 1 and Fig. 6.
WBCT assay. WBCT is a modification of the Lee–White clotting time using two
siliconized glass tubes (Becton Dickinson, Rutherford, NJ) at 28 C (ref. 37). One
ml of whole blood was drawn and 0.5 ml blood was distributed into each tube. A
timer was started. After one minute, one tube was tilted every 30 s, the other left
undisturbed. When a clot formed in the tilted tube, the second tube was then tilted
every 30 s until a clot formed. The time for formation of a fully gelled clot in the
second tube was recorded as the WBCT. Blood was collected from a
haemostatically normal (WBCT 7.5-12.5 min) and the three experimental dogs
(F20, I42 and M64) before and after G-PBC transplant if animals had not been
treated with plasma for at least 1 month.
Inhibitor assay to detect immune response to human FVIII. Canine blood
plasma (F20, I42 and M64) was screened for inhibitors with an aPTT mixing assay
that detects inhibitory antibodies to either coagulation factor VIII or IX as pre-
viously described55–57. Briefly, test plasmas are incubated in a 1:1 mix with normal
plasma for 2 h at 37 C and then the incubated mixture is analysed using standard
aPTT reagents. Plasma from haemophilia A dogs with known BIU titres that
crossreact with and inhibit human FVIII (positive control) and plasma from dogs
without inhibitors (negative control) were assayed concurrently for comparison.
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